After years of backbiting, practitioners of kyphoplasty and vertebroplasty have finally found an issue upon which they can agree. They need a randomized controlled clinical trial.
Heated exchanges and finger-pointing for alleged clinical flops are the norm between the two camps. However, there is simply no credible evidence to rate one technique above the other for management of osteoporotic vertebral compression fractures, said Dr. Avery J. Evans, an associate professor of radiology and neurosurgery at the University of Virginia, at a special focus session at the RSNA meeting.
Physicians recognize that each technique has shortcomings. For instance, patients undergoing vertebroplasty for fractures caused by tumors seem to have higher complication rates. Some data also suggest that increased vertebral pressure following these interventions can cause new vertebral fractures. Most available references on these procedures, however, come from in vitro biomechanical data, incidental or anecdotal reports, or retrospective, nonrandomized studies.
"Physicians cannot establish the success or complication rate of either technique without a randomized controlled trial," Evans said.
Overall risks seem similar. But the multiple factors influencing the outcome of each procedure have not been properly addressed, said Dr. David F. Kallmes, an interventional neuroradiologist at the Mayo Clinic in Minnesota.
"Until these issues are clearly resolved, we need to have an honest discussion with patients about these procedures," he said. "And we also need to make sure we do our best to manage the disease, not just the symptoms. We definitely need a trial."
Several groups in the U.S. and Canada have set up protocols for prospective studies. The first multicenter randomized controlled trial with a significant patient population is expected to be announced this year.
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.